Drug Approval | September 23, 2024
Bavarian Nordic receives EMA approval of mpox vaccine for adolescents
MVA-BN approved for use against mpox and smallpox in adolescents 12-17 years of age after expedited review with EMA
MVA-BN approved for use against mpox and smallpox in adolescents 12-17 years of age after expedited review with EMA
This approval reflects company’s unwavering commitment that the quality assurance
Doses will be ready to ship to applicable European Union (EU) member states as soon as possible upon European Commission (EC) authorization
New indication supported by the MANDARA trial which showed nearly 60% of patients achieved remission and 41% of patients fully stopped taking oral corticosteroids
The exclusive hospital will help address health complexities concerning women and children, specializing in high-end obstetrics, comprehensive gynecological, neonatal & pediatric care
Glenmark Pharmaceuticals Limited has informed that the USFDA has issued Form 483 with zero observations
Palivizumab (Synagis) is indicated for the prevention of serious lower respiratory tract disease requiring hospitalization caused by RSV in children at high risk for RSV disease
Stable profits, low leverage to keep credit profiles comfortable
Based out of Boston, Vivek will build on the foundation created by Vaidheesh, and will help build a stronger customer connect and further drive global expansion of the platform
A multi-disciplinary team of senior physicians opted to use Zidebactam/Cefepime under compassionate use
Subscribe To Our Newsletter & Stay Updated
